Bay­er and AskBio re­veal ear­ly safe­ty da­ta for Parkin­son's gene ther­a­py, plot PhII study

Bay­er and its sub­sidiary AskBio tout­ed ear­ly da­ta from a small, ear­ly tri­al eval­u­at­ing the safe­ty of its gene ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.